



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/759,732	01/15/2004	Oren A. Mosher	017761-003610US	6876
20350	7590	12/29/2005	EXAMINER	
TOWNSEND AND TOWNSEND AND CREW, LLP TWO EMBARCADERO CENTER EIGHTH FLOOR SAN FRANCISCO, CA 94111-3834			WILLIAMS, KENNETH C	
			ART UNIT	PAPER NUMBER
			3739	

DATE MAILED: 12/29/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/759,732

Applicant(s)

MOSHER ET AL.

Examiner

Kenneth C. Williams

Art Unit

3739

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 02 December 2005.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-47 is/are pending in the application.
- 4a) Of the above claim(s) 18,29-35 and 45-47 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-17, 19-28 and 36-44 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 07 June 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date 6/7/2004, 8/5/2005.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_.

## DETAILED ACTION

### *Election/Restrictions*

1. Applicant's election of Species II in the reply filed on December 2, 2005 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).
2. Claims 18, 29-33 and 45-47 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on December 2, 2005.
3. In addition to the withdrawn claims mentioned above, Claims 34 and 35 are also withdrawn because of their dependence on a withdrawn claim.

### *Specification*

4. The disclosure is objected to because of the following informalities:
  - a. Page 8, line 31, "obturator intemus muscle", should be changed to read --obturator internus muscle--.
  - b. Page 9, line 31 and Page 12, line 20, "reciprocatably", should be changed to read --reciprocately--.
  - c. Page 12, line 1, "will may", should be changed to read --may--.
  - d. Page 13, line 14, "palpatatable" should be changed to --palpatory--.
  - e. Page 18, line 30, "elongate" should be changed to read --elongated--.

- f. Page 23, line 19, "in maintained" should be changed to read --is maintained--.

Appropriate correction is required.

***Claim Rejections - 35 USC § 102***

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

6. Claims 23-28 and 36-44 are rejected under 35 U.S.C. 102(b) as being anticipated by Ingle et al. (U.S. Patent No. 6091995).

a. In regards to Claim 23, Ingle et al. discloses a system for treating incontinence comprising "a probe body" (See Figure 1, element 10) and "at least one energy delivery element" (See Figure 1, elements 18 and 20).

b. In regards to Claim 24, Ingle et al. discloses a system for treating incontinence (See Claim 23 Rejection). Ingle et al. further discloses, "at least one cooling element supported by the probe body" (See column 13, lines 57-59).

c. In regards to Claim 25, Ingle et al. discloses a system for treating incontinence (See Claim 24 Rejection). Ingle et al. further discloses, "at least one energy delivery element comprises a plurality of electrodes" (See column 22, line 63 – column 23, line 4).

d. In regards to Claim 26, Ingle et al. discloses a system for treating incontinence (See Claim 25 Rejection). Ingle et al. further discloses, "the

electrodes have a width of at least 20 mm and a length of less than 8 mm" (See column 4, lines 39-47; see also column 7, lines 30-32).

e. In regards to Claim 27, Ingle et al. discloses a system for treating incontinence (See Claim 25 Rejection). Ingle et al. further discloses, "at least one energy delivery element comprises a distal or proximal pair of electrodes on the probe body" (See Figure 1, elements 18 and 20).

f. In regards to Claim 28, Ingle et al. discloses a system for treating incontinence (See Claim 24 Rejection). Ingle et al. further discloses, "at least one energy delivery element comprises a pair of elongated electrodes" (See Figure 12A, elements 56 and 58).

g. In regards to Claims 38, 39, 40 and 43, Ingle et al. discloses a system for treating incontinence (See Claim 23 Rejection). Ingle et al. further discloses, "the treatment volume comprises tissue separated from the aligned probe body by a distance within a range of about 2 to 8 mm" and "the treatment volume is separated from a urethra by at least about 1 cm" (See column 6, lines 22-35), "the treatment volume is offset laterally from the urethra to a right side or left side" (See Figure 4 and column 12, lines 3-12) and "the treatment volume comprises between about 300 cubic millimeters and about 800 cubic millimeters of collagenous tissue" (See column 4, lines 29-33). It is the Examiner's position that Ingle et al. is inherently capable of meeting these functional limitations.

h. In regards to Claims 41 and 42, Ingle et al. discloses a system for treating incontinence (See Claim 23 Rejection). Ingle et al. further discloses "the

Art Unit: 3739

treatment volume has a length orientation extending along the urethra, a depth orientation extending between collagenous tissue and the probe body, and a width that is greater than the length of the treatment volume” or “the treatment volume has a length orientation extending along the urethra, a depth orientation extending between collagenous tissue and the probe body, and a width that is less than the length of the treatment volume” (See column 6, lines 22-35). It is the Examiner’s position that Ingle et al. is inherently capable of meeting these functional limitations.

i. In regards to Claim 44, Ingle et al. discloses a system for treating incontinence (See Claim 23 Rejection). Ingle et al. further discloses “at least one energy delivery element heats the treatment volume of tissue by the application of bipolar radio frequency energy” (See column 10, lines 21-32).

***Claim Rejections - 35 USC § 103***

7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

8. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.

4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
9. Claims 1-17 and 19-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ingle et al. (U.S. Patent No. 6091995).
  - a. In regards to Claim 1, Ingle et al. discloses a method for treating incontinence comprising, "aligning a probe body" (See column 4, lines 23-26). Ingle et al. does not disclose, "heating a treatment volume of at least 100 cubic millimeters of the collagenous tissue". It would have been obvious to one of ordinary skill in the art at the time of the invention to use the teaching of the Ingle et al. reference to heat a treatment volume of at least 100 cubic millimeters because one of ordinary skill in the art would be able to determine the optimum area to treat to relieve patient discomfort (See column 4, lines 29-33).
  - b. In regards to Claim 2, Ingle et al. discloses a method for treating incontinence (See Claim 1 Rejection). Ingle et al. does not disclose "the treatment volume is separated from a urethra by at least about 1 cm". It would have been obvious to one of ordinary skill in the art at the time of the invention to use the teaching of the Ingle et al. reference to treat a volume at least 1 cm apart from the urethra because one of ordinary skill in the art would be able to direct treatment to the optimum tissue location (See column 6, lines 22-35).
  - c. In regards to Claim 3, Ingle et al. discloses a method for treating incontinence (See Claim 2 Rejection). Ingle et al. does not disclose "the treatment volume is offset laterally from the urethra to a right side or left side". It would have been obvious to one of ordinary skill in the art at the time of the

invention to use the teaching of the Ingle et al. reference to position the treatment probe in the optimum tissue location to relieve patient discomfort (See Figure 4; see also column 12, lines 3-12).

d. In regards to Claim 4, Ingle et al. discloses a method for treating incontinence (See Claim 2 Rejection). Ingle et al. further discloses, "the treatment volume is heated to a temperature of at least 70°C for a time of at least 30 seconds" (See column 21, lines 18-24). Ingle et al. does not disclose "the treatment volume comprises at least 300 cubic millimeters of collagenous tissue" and "the treatment volume is offset laterally from the urethra to a right side of a patient" or "the treatment volume is offset laterally from the urethra to a left side of a patient". It would have been obvious to one of ordinary skill in the art at the time of the invention to use the teaching of Ingle et al. to heat a treatment volume of at least 300 cubic millimeters and the treatment volume is offset laterally from the urethra to a right side or left side of the patient because one of ordinary skill in the art would be able to determine the optimum area to treat to relieve patient discomfort (See column 4, lines 29-33 and See Figure 4; see also column 12, lines 3-12).

e. In regards to Claim 5, Ingle et al. discloses a method for treating incontinence (See Claim 1 Rejection). Ingle et al. further discloses "the treatment volume is heated to at least about 65°C for at least about 100 seconds" (See column 4, lines 30-34 and See column 21, lines 18-24).



- f. In regards to Claim 6, Ingle et al. discloses a method for treating incontinence (See Claim 1 Rejection). Ingle et al. further discloses "the treatment volume is heated to at least about 75°C for at least about 10 seconds" (See column 21, lines 18-24).
- g. In regards to Claim 7, Ingle et al. discloses a method for treating incontinence (See Claim 1 Rejection). Ingle et al. further discloses, "applying a dwell time after a desired heating temperature is achieved so as to increase treatment tissue volume" (See column 21, lines 18-24 and See column 22, lines 51-52).
- h. In regards to Claims 8 and 9, Ingle et al. discloses a method of treating incontinence (See Claim 1 Rejection). Ingle et al. does not disclose "the treatment volume has a length orientation extending along the urethra, a depth orientation extending between collagenous tissue and the probe body, and a width that is greater than the length of the treatment volume" or "the treatment volume has a length orientation extending along the urethra, a depth orientation extending between collagenous tissue and the probe body, and a width that is less than the length of the treatment volume". It would have been obvious to one of ordinary skill in the art at the time of the invention to use the Ingle et al. reference because one of ordinary skill in the art would be able to determine the optimum volume necessary to treat to relieve patient discomfort (See column 23, lines 31-50).

i. In regards to Claims 10 and 11, Ingle et al. discloses a method of treating incontinence (See Claim 1 Rejection). Ingle et al. further discloses, "registering a position of the treatment volume along an axis of the urethra with reference to a guide body disposed within the urethra" and "registering a position of the treatment volume with reference to bone" (See column 6, lines 6-21).

j. In regards to Claim 12, Ingle et al. discloses a method of treating incontinence (See Claim 1 Rejection). Ingle et al. further discloses, "the probe is aligned so that an intermediate tissue is disposed between the probe body and the treatment volume" (See column 23, lines 31-50).

k. In regards to Claims 13 and 14, Ingle et al. discloses a method of treating incontinence (See Claim 12 Rejection). Ingle et al. does not disclose, "the treatment volume comprises tissue separated from the aligned probe body by a distance within a range of about 2 to 8 mm" or "the treatment volume comprises tissue separated from the aligned probe body by a distance within a range of about 2 to 4 mm". It would have been obvious to one of ordinary skill in the art at the time of the invention to use the Ingle et al. reference because one of ordinary skill in the art would be able to determine the optimum distance to locate the treatment volume to relieve patient discomfort (See column 6, lines 22-35).

l. In regards to Claim 15, Ingle et al. discloses a method of treating incontinence (See Claim 12 Rejection). Ingle et al. further discloses, "heating is performed so as to inhibit necrosis of the intermediate tissue" (See column 13, lines 44-54).

- m. In regards to Claim 16, Ingle et al. discloses a method of treating incontinence (See Claim 15 Rejection). Ingle et al. further discloses, "heating is performed while cooling of the intermediate tissue" (See column 13, lines 49-59).
- n. In regards to Claim 17, Ingle et al. discloses a method of treating incontinence (See Claim 15 Rejection). Ingle et al. further discloses, "heating is performed without cooling of the intermediate tissue" (See column 21, lines 4-11).
- o. In regards to Claim 19, Ingle et al. discloses a method of treating incontinence (See Claim 1 Rejection). Ingle et al. further discloses, "heating is performed by tip movement of at least a pair of electrodes supported by the probe body" (See column 12, lines 3-23).
- p. In regards to Claim 20, Ingle et al. discloses a method of treating incontinence (See Claim 19 Rejection). Ingle et al. does not disclose, "the treatment volume increases as the tip movement speed decreases". It would have been obvious to one of ordinary skill in the art at the time of the invention to use the Ingle et al. reference because one of ordinary skill in the art would be able to determine the tip movement speed necessary to treat the optimum treatment volume (See column 21, lines 18-28).
- q. In regards to Claims 21 and 22, Ingle et al. discloses a method of treating incontinence (See Claim 1 Rejection). Ingle et al. does not disclose, "the treatment volume comprises at least 300 cubic millimeters of collagenous tissue" and "the treatment volume comprises between about 100 cubic millimeters and

about 800 cubic millimeters of collagenous tissue". It would be obvious to one of ordinary skill in the art at the time of the invention to use the Ingle et al. reference to heat a treatment volume of at least 300 cubic millimeters or between 100 and 800 cubic millimeters because one of ordinary skill in the art would be able to determine the optimum area to treat to relieve patient discomfort (See column 4, lines 29-33).

10. Claims 36 and 37 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ingle et al. (U.S. Patent No. 6091995) in view of Presthus et al. (U.S. Patent No. 6685623).

a. In regards to Claim 36, Ingle et al. discloses a system for treating incontinence (See Claim 23 Rejection). Ingle et al. does not disclose "a guide body disposable within a urethra". Attention is directed to the Presthus et al. reference, which in an analogous field of endeavor discloses a guide body or shaft used to assist in the proper positioning of the probe body and treatment surface with the target tissue (See Presthus et al. column 4, lines 36-39). It would have been obvious to one of ordinary skill in the art at the time of the invention to modify the device of Ingle et al. with the device of Presthus et al. to accurately position a treatment surface adjacent a target tissue.

b. In regards to Claim 37, Ingle et al. discloses a system for treating incontinence (See Claim 36 Rejection). Ingle et al. does not disclose "the guide body further comprises axial position indicators or electromagnetic transmitters". Attention is directed to the Presthus et al. reference, which in an analogous field

of endeavor discloses a guide body with serrations that allow for incremental axial positioning (See Presthus et al. column 6, lines 51-60). It would have been obvious to one of ordinary skill in the art at the time of the invention to modify the device of Ingle et al. with the device of Presthus et al. to accurately position a treatment surface adjacent a target tissue.

11. Claim 36 is rejected under 35 U.S.C. 103(a) as being unpatentable over Ingle et al. (U.S. Patent No. 6091995) in view of Roy et al. (U.S. Patent No. 6156060).


In regards to Claim 36, Ingle et al. discloses a system for treating incontinence (See Claim 23 Rejection). Ingle et al. does not disclose Ingle et al. does not disclose "a guide body disposable within a urethra". Attention is directed to the Roy et al. reference, which in an analogous field of endeavor discloses a rigid shaft used to orient the treatment surface with the target tissue (See Roy et al. column 9, lines 16-34). It would have been obvious to one of ordinary skill in the art at the time of the invention to modify the device of Ingle et al. with the device of Roy et al. to accurately position a treatment surface adjacent a target tissue.

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kenneth C. Williams whose telephone number is (571) 272-8161. The examiner can normally be reached on Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Linda Dvorak can be reached on (571) 272-4764. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



LINDA C. M. DVORAK  
SUPERVISORY PATENT EXAMINER  
GROUP 3700

KCW